News & Publications
Press Release: Cambrian Biopharma Announces Licensing Agreement to Develop Selective mTOR Inhibitors
16
February
22
Press Release: Cambrian Biopharma Announces Licensing Agreement to Develop Selective mTOR Inhibitors
16
February
22
75 mins to watch
14
April
21
Foresight Institute Biotech & Health Extension Webinar: “James Peyer: How to Fund and Build Geroprotectors”
In this session, James Peyer, PhD, CEO of Cambrian Biopharma, shares his overview of the longevity biotech industry with insights into what it actually means to be a longevity biotech company, how Cambrian functions, what is a "DisCo model" (and why it will most likely replace single asset biotech companies model), and the barriers preventing us from starting clinical trials with the first geroprotectors.
Visit
Visit
8 mins to read
23
March
21
Longevity.Technology: Cambrian Biopharma – CEO James Peyer Q&A
An exclusive Q&A with Cambrian Biopharma’s CEO, James Peyer – a discussion of the Hallmarks of Aging and classifying aging as a disease.
Visit
Visit
6 mins to read
22
March
21
Longevity.Technology: Cambrian Biopharma – COO Juliette Han Q&A
An exclusive Q&A with Cambrian Biopharma’s Chief Operating Officer, Juliette Han.
Visit
Visit
105 mins to read
1
March
21
Nature Reviews Drug Discovery (May 2021 Cover Story): Strategies for delivering therapeutics across the blood–brain barrier (Georg C. Terstappen; EVP, Drug Discovery)
A review of recent developments and challenges related to selected blood–brain barrier-crossing strategies — with a focus on non- invasive approaches such as receptor-mediated transcytosis and the use of neurotropic viruses, nanoparticles and exosomes — and analysis of their potential in the treatment of CNS disorders.
Visit
Visit
60 mins to listen
18
February
21
The Pomp Podcast with Anthony Pompliano: James Peyer on Longevity and Curing Cancer
James Peyer is the Co-Founder and CEO of Cambrian Biopharma, a Distributed Development Company developing therapeutics targeting the biology of aging. Cambrian builds, finances, and manages a pipeline of therapeutics. In this conversation, we discuss molecular damage, adding healthy years to your life, prevention vs reversal of diseases, and distributed drug companies.
Visit
Visit
9 mins to read
11
February
21
Longevity.Technology: International Day of Women and Girls in Science
In 2015, The UN declared February 11th the “International Day of Women and Girls in Science." Today marks the sixth celebration of the vital role women and girls play in science, technology and innovation. We are delighted to showcase some of the women whose work we have covered or will be covering and to play our part in promoting women and girls in science.
Visit
Visit
7 mins to read
11
February
21
TrialSite News: Anti-Aging Distributed Drug Discovery Venture Cambrian Biopharma Announces $60m Funding & First IPO of Portfolio Company
Cambrian Biopharma, a new type of biotech venture raising $60 million to execute on a model known as the “Distributed Development Company” or “DisCo,” that is, a multi-asset company combining the advantages of the standard biotech firm with those of a venture capital fund and biotech incubator, to establish a platform for the development of new anti-aging therapeutics.
Visit
Visit
65 mins to read
9
February
21
Nanoscale Advances (May 2021 Cover Story): Trafficking of JC virus-like particles across the blood–brain barrier (Georg C. Terstappen; EVP, Drug Discovery)
A study on John Cunningham virus-like particles (JC VLPs) and their potential use in developing a delivery system for transport of genes and small molecule cargoes across the blood-brain barrier (BBB).
Visit
Visit
5 mins to read
9
February
21
Longevity.Technology: Cambrian Biopharma exits stealth with $60m and affiliate IPO
Cambrian Biopharma, a distributed development company, exits stealth mode with the announcement that it has raised $60 million in private financing to develop medicines to extend healthy lifespan.
Visit
Visit
In the News
Bloomberg
22
April
22
The $7.6 Trillion Quest for Longer Life
The new field of longevity science aims to slow aging and make late-life more livable. But will the science ever work? And if so, will it only be for the super rich?
Visit
Fierce Biotech
26
October
22
Cambrian secures $100M series C for Roivant-like approach to biotech creation with goal to slow down human aging
Cambrian will likely test two of its first three compounds in rare childhood disorders "because the mechanisms work a little bit like fast-aging syndromes," said James Peyer, Ph.D., CEO and co-founder of the biotech.
Visit